Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Apr;3(4):585-591.
doi: 10.3892/etm.2012.474. Epub 2012 Feb 3.

Therapeutic strategies for head and neck cancer based on p53 status

Ichiro Ota  1 , Noritomo Okamoto, Katsunari Yane, Akihisa Takahashi, Takashi Masui, Hiroshi Hosoi, Takeo Ohnishi
Affiliations

Therapeutic strategies for head and neck cancer based on p53 status

Ichiro Ota et al. Exp Ther Med. 2012 Apr.

Abstract

Squamous cell carcinomas of the head and neck (HNSCC) are one of the most common types of cancers worldwide, and despite advances in treatment, they still represent a clinical challenge. Inactivation of one or more components in the p53 signaling pathway is an extremely common event in human neoplasia, including HNSCC. The loss of p53 function is responsible for increased aggressiveness in cancers, while tumor chemoresistance and radioresistance can depend on deleted p53 expression, or on the expression of mutated-p53 proteins. Thus, consideration and manipulation of the p53 status during HNSCC cancer therapy should be considered. This review discusses the p53 signaling pathways activated by various cellular stresses, including exposure to cancer therapies. The recognition of the p53 status in cancer cells is a significant factor and could provide valuable assistance during the selection of an effective therapeutic approach.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
p53-dependent and -independent therapeutic strategies for cancer cells. Circles, p53 status of cancer cells; black squares, cancer therapeutic tool; white squares, enhancer for cancer therapeutic tool; thin arrows, enhancement; dashed arrows, partial enhancement; thick arrows, therapeutic pathway. MDM2, murine double minute 2; XIAP, X-chromosome-linked inhibitor of apoptosis protein; wtp53, wildtype p53; mp53, mutant p53; siRNA, small interference RNA.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. - PubMed
    1. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357:2552–2561. - PMC - PubMed
    1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310. - PubMed
    1. Guimaraes DP, Hainaut P. TP53: a key gene in human cancer. Biochimie. 2002;84:83–93. - PubMed
    1. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol. 2003;39:222–231. - PubMed